Tag:
axitinib
Latest Headlines
Latest Headlines
Cancer drug developers angling for center stage at ASCO
Later this week the cancer drug research crowd will examine a tsunami of abstracts filed ahead of the ASCO meeting in early June in the hopes of finding a few gems.
Pfizer nails unanimous expert panel vote for kidney cancer drug
Pfizer's ( $PFE ) cancer drug team nailed a unanimous endorsement from an FDA expert panel this morning following its review of axitinib , setting it on a path to a likely approval for patients with
Pfizer seeking European approval on one of its top cancer prospects
With Pfizer investigators preparing to go into some detail at ASCO to make their case for axitinib as a treatment for late-stage kidney cancer, its regulatory team has pushed ahead with an
Pfizer lays out its R&D survival strategy
While Wall Street has been transfixed by signs that Pfizer CEO Ian Read is preparing to sell off large chunks of its business so it can concentrate on pharmaceutical sales and new drug development to
Pfizer cancer drug fails Phase III trial
Pfizer shuttered a late-stage trial of a pancreatic cancer drug after its data monitoring board determined that the treatment--designed to shrink tumors--had failed to extend patients' survival time.
